Intuitive Surgical (ISRG) closed Friday at $424.64 on the Nasdaq, a modest gain of 0.24% for the session, but the stock still ended the holiday-shortened week down approximately 3.1% from its May 22 close of $438.10. The decline came even as the broader market surged to new highs, with the S&P 500 rising 1.4% for the week and the Nasdaq Composite gaining 2.4%, marking the ninth consecutive weekly advance for the S&P 500, according to the Associated Press.
The divergence between Intuitive Surgical's performance and the broader market has put a spotlight on the robotic surgery maker's ability to convert its strong procedure growth into sustained share price gains. Investors are weighing the company's solid first-quarter results against headwinds including tariff risks and a decline in U.S. bariatric procedures.
Leadership Change at a Critical Juncture
Intuitive Surgical announced a key change in its commercial leadership in a May 28 SEC filing. Henry Charlton, currently serving as chief commercial and marketing officer, will transition to the role of senior vice president of global business operations effective July 1. Taylor Patton, who has been global senior vice president for endoluminal, will step into the chief commercial officer role at that time.
CEO Dave Rosa described the move as an internal transition at a pivotal point in the company's growth trajectory. Rosa stated that Patton's long tenure at Intuitive makes him "uniquely positioned" to take on the commercial leadership role. Patton himself emphasized that customers are increasingly focused on "meaningful and differentiated outcomes" and on reducing the total cost of treatment.
Procedure Growth Drives Revenue
The company's first-quarter results, reported on April 21, showed revenue climbing 23% year-over-year to $2.77 billion. Procedure growth, a key metric for the company, was robust: da Vinci procedures increased approximately 16%, while Ion procedures jumped roughly 39%. Intuitive Surgical installed 431 da Vinci systems during the quarter, including 232 of the new da Vinci 5 models.
Procedure growth is a critical indicator for Intuitive because more surgeries typically translate into higher sales of instruments, accessories, and service contracts. However, the company faces challenges in certain segments. On the earnings call, management noted that U.S. bariatric procedures fell about 10% as demand softened with the rise of GLP-1 weight-loss drugs. Additionally, the Chinese market remains difficult due to fewer tenders, increased competition, and ongoing pricing pressure.
Tariff Risks and Margin Outlook
Despite the strong operational performance, tariff risks are a significant concern. Intuitive Surgical projects non-GAAP gross margin of 67.5% to 68.5% of revenue in 2026, after factoring in an expected tariff impact of approximately 1.0%. The company has warned that additional tariffs could have a material adverse effect on results.
The broader market's resilience provided some support for the stock, but macro risks remain. Reuters reported that investors are now focused on the June 5 U.S. payrolls report, where a poll forecasts 85,000 new jobs and an unemployment rate of 4.3%. Liz Ann Sonders of the Schwab Center for Financial Research told Reuters that a strong jobs number combined with higher inflation could reset expectations for Federal Reserve policy.
Competitive Landscape
Intuitive Surgical's performance on Friday stood out in the medtech space, as some competitors moved lower. Medtronic lost 2.33% and Stryker finished down 0.83% in the session, according to MarketWatch data. Investors have been selectively rotating among device names recently, with Intuitive's relative strength reflecting confidence in its long-term growth story despite near-term uncertainties.
With U.S. markets closed on Saturday, trading resumes Monday. The holiday-shortened week left investors with just four sessions to adjust positions, but the focus remains on whether Intuitive can continue to execute on its growth strategy amid tariff headwinds and evolving competitive dynamics.
